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aterials  and  methods:  Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents
n untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate
ORR), and grade 3–4 (G3–4) hematologic toxicities.
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esults:  Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI:
.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also
ore frequent in this group.
onclusion:  This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-
ate with increase of severe hematological toxicities.
 2015 Elsevier Ireland Ltd. All rights reserved.
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.  Introduction
Lung cancer is the most important cause of cancer-related
eath worldwide. Non-small-cell lung cancer (NSCLC) rep-
esents about 75–80% of overall lung cancer cases, and
ost patients have developed advanced disease at diagnosis.
owever the management of advanced NSCLC has signifi-
antly improved during last decade. Innovative oral targeted
olecules, such as the anti-EGFR tyrosine kinase inhibitors
TKIs), gefitinib, erlotinib, and afatinib, or the ALK inhibitor,
rizotinib, have shown their superiority in terms of response
ate, progression-free survival (PFS) and quality of life (QoL)
ompared with standard chemotherapy for tumours harbou-
ing an activating EGFR mutation or ALK-rearrangement,
espectively [1–5].
Actually the use of targeted drugs is recommended as
rst-line treatment in 10–15% of NSCLC patients, selected
ccording to their mutational status, while platinum-based
ombination remains the standard treatment of the majority of
ild-type NSCLC patients with performance status (PS) 0–1.
hereas single agent chemotherapy is still recommended as
he best option in the first-line treatment of PS 2 patients,
latinum-based combination is considered as a possible alter-
ative [6]; so the best treatment of these subset of patients is
till uncertain and debated. PS 2 patients represent a signif-
cant proportion of the advanced NSCLC population (up of
0–40% of cases), even if the exact prevalence is still not cer-
ain [7,8]. PS is a general measure of the patient’s functional
tatus: it defines the impact of tumour symptoms, together
ith other pre-existing medical problems and comorbidities,
n a patient’s daily function and ability of self-care.
The most recent scale is the Performance Status according
o the “Eastern Cooperative Oncology Group” (ECOG PS),
 five points scale based on the level of symptoms interfer-
nce with normal activity and on the proportion of waking
ours spent in bed [9]. In fact, PS is also the most impor-
ant independent prognostic factor in advanced NSCLC and
 strong predictor of survival and adverse events [10]. PS
 is associated with lower RR, shorter survival and higher
isk for severe toxicity when compared to PS 0–1 [11]. How-
ver these patients represent a heterogeneous and large group,
ecause PS 2 may be due to tumour-related symptoms (such
s pain, fatigue, weight loss), pre-existing comorbidities (car-
iovascular or obstructive pulmonary diseases, peripheral
ascular diseases, kidney or liver diseases and age-related
ecline in functional status), or both, and actually we have we agent
ot still known the real impact of these different factors on PS
12]. PS2 patients have been traditionally underrepresented
r completely excluded by clinical trials. Subsequently treat-
ent recommendations or guidelines about this subgroup of
SCLC patients are largely lacking [13].
Despite a worse prognosis than the PS 0/1 group, PS 2
atients appear to have a survival benefit from chemother-
py, as emerging from subgroup analysis of several trials and
s previously showed in a meta-analysis of 1995, and subse-
uently updated in 2008 [14], which compared chemotherapy
ith newer third generation agents with or without platinum-
ompounds to best supportive care in advanced NSCLC
atients, showing a 1-year survival benefit of 8% (from
0% to 28%) in favour of chemotherapy (more evident
or platinum-based regimens) in general population, and an
ncrease of 6% for PS2 subgroup. However, these patients,
ue to their frailty and lack of studies dedicated, have been
istorically considered not eligible for aggressive treatment
ased on combined therapies. So single-agent therapy with
ew generation cytotoxic agent such as gemcitabine, vinorel-
ine or taxane has been considered as the treatment of choice,
s stated by the European experts panel consensus meeting
13] and also recommended by international guidelines.
Until now PS 2 patients have been considered not
uitable combination chemotherapy as showed for elderly
atients with advanced NSCLC [15–17]. However, in the
ast years, new prospective randomized phase III trials have
een performed to evaluate the efficacy and tolerability of
latinum-based doublet chemotherapy compared to single
gent in this subset of patients, revealing unexpected results
18,19].
The aim of this meta-analysis is to combine and analyse
imultaneously all randomized trials comparing platinum-
ased doublets and single-agent therapy in NSCLC and PS2
atients. This work could allow a stronger and more precise
ssessment of efficacy (1-year-survival rate and ORR) and
oxicity profile of these treatments for the first-line treatment
f PS2 patients with advanced NSCLC.
. Materials  and  methods
.1.  Search  for  clinical  trialsWe performed our meta-analysis according to a predefined
ritten protocol. We searched for all published randomized
3  Oncology/Hematology 95 (2015) 306–317
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rials, which compared efficacy and safety of platinum-
ased doublets to single-agent chemotherapy in untreated
atients with NSCLC either wholly or partially dedicated
o PS2. Publications were identified by an electronic search
sing PubMed online, updated in September 2014. The
earch for publications was made by other databases includ-
ng the Cochrane Library. However the search on PubMed
llowed the widest collection of publications about this topic.
he following search terms were used: “randomized con-
rolled trial”, “PS 2”, “performance status of 2”, “NSCLC”,
non-small cell lung cancer”, “lung carcinoma”, “NSCLC
reatment”. The results were supplemented with manual
earches of American Society of Clinical Oncology meet-
ng proceedings, references of selected articles and published
eviews. A systematic review on this topic in the Cochrane
atabase of systematic reviews was not found.
.2.  Selection  criteria
According to this search clinical trials were taken into
ccount if they had to fulfil all the following inclusion criteria:
1) only patients with NSCLC were included; (2) randomized
hase II or III clinical trials; (3) clinical trials specifically or
artially devoted to PS2 patients; (4) comparison between
latinum-based doublets and single agent chemotherapy at
tandard doses as first-line treatment; (5) availability of spe-
ific data for PS 2 patients about 1-year survival rate (1y-SR),
bjective response rate (ORR), and proportion of patients
ho experienced grade 3 and 4 (G3–4) haematological toxi-
ities.
.3.  Data  extraction
Two authors independently selected studies according to
he aforementioned inclusion criteria, and extracted and orga-
ized data according to the characteristics of the studies (i.e.
rst author name, journal and year of publication, design,
articipants, intervention and outcomes), baseline charac-
eristics of patients (i.e. age, stage, performance status),
utcome measures (i.e. 1y-SR, ORR) and G3–4 haematolog-
cal toxicity rates. Data extraction was conducted according
o the Preferred Reporting Items for Systematic Reviews and
eta-Analyses (PRISMA) guidelines [20]. The proportion of
atients for each outcome was calculated based on the per-
entages reported in included trials, when it was not reported
s absolute number.
.4.  Statistical  analysis
Primary outcome was 1y-SR, defined as the percentage
f patients who remain alive one year after randomization.
econdary endpoint was ORR, defined as the percentage
f patients who have a complete or partial tumor response
ccording to World Health Organization (WHO) criteria or
esponse Evaluation Criteria in Solid Tumors (RECIST).
inally, severe hematologic toxicities, including grade 3–4
e
t
p
nFig. 1. Flow-chart of trials selection.
naemia, neutropenia and thrombocytopenia, graded accord-
ng to the National Cancer Institute Common Toxicity
riteria (NCI-CTC). The number of events (i.e. patients
live after 1 year, objective responses and grade 3–4 side
ffects) was extracted from each study or calculated from
he percentage provided, and the proportion of patients was
alculated for each arm; ORs (odds ratios) were presented
f available. An OR greater than 1 indicated a benefit of
latinum-doublet over the single agent, and subsequently
 higher 1-Y-SR, RR, but also a higher grade 3–4 toxic-
ty rate. The heterogeneity between trials was tested using
he Cochran Q-test. A meta-analysis of ORs was performed
o calculate a pooled OR for each outcome using a fixed-
ffect or random-effect, based on statistical significance of
-test, according to Mantel–Haenszel method. All statistical
nalyses were performed with NCSS software (2009 version;
aysville, Utah).
.  Results
Our PubMed search, performed in September 2014, found
875 publications. Among these, 1632 publications were
xcluded because the clinical trials were not randomized;
he remaining 243 trials were analysed accurately. 235
ublications were considered ineligible because they did
ot compare platinum-based doublets with single-agent
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Table 1
Primary and secondary endpoints of the 6 randomized trials included in the meta-analysis.
Trial (reference) 1y-SR n* (%) ORR n.* (%) G3–4 Anaemia n.*
(%)
G3–4 Neutropenia
n.* (%)
G3–4 Thrombocytopenia
n.* (%)
Zukin et al. [18] 41/103(40)
22/102(21.9)
19/79(24)
7/67(10.5)
12/103 (11.6)
4/102 (3.9)
7/103 (6.8)
1/102 (1)
1/103 (1)
0/102 (0)
Morabito et al. [19] N/A 5/28(18)
1/28(4)
5/28 (18)
0/28 (0)
3/28 (10.7)
1/28 (3.6)
6/28 (21.5)
1/28 (3.5)
Kosmidis et al. [24] 9/43(20)
8/47(17.8)
6/43(14)
2/47(4)
3/43 (7)
1/47 (2)
3/43 (7)
1/47 (2)
3/43 (7)
0/47 (0)
Reynolds et al. [21] 26/85(31.3)
18/85(21.2)
16/85(18.8)
5/85(5.9)
12/85 (14)
6/85 (7)
46/85 (54)
9/85 (10.5)
35/85 (41)
3/85 (3.5)
Lilenbaum et al. [22] 9/49(18)
5/50(10)
12/49(24)
5/50(10)
N/A N/A N/A
Le Chevalier et al. [23] 11/75(14.7)
7/46(15.2)
N/A N/A N/A N/A
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P-y-SR, 1-year survival rate; ORR, overall response rate; G3–4, grade 3–4; 
* The number of patients reported corresponds to the number of patients e
hemotherapy. Furthermore, two other trials were excluded
ecause no specific data for PS2 patients were reported. So,
fter a careful selection procedure, only six trials met our
nclusion criteria and were included in our meta-analysis.
verall 741 patients were included in these six trials (Fig. 1).
ive publications [18,19,21–23] are about randomized phase
II trials and one was a randomized phase II trial [24].
our studies [18,19,21,24] were specifically devoted to PS2
atients, while two trials [22,25] reported subgroup analysis
or PS2 patients (18 and 20%, respectively) within larger
andomized phase III trials. All trials compared a platinum-
ased doublet with single-agent chemotherapy; four of these
18,21,22,24] compared carboplatin-based doublet with
ingle agent chemotherapy: carboplatin plus pemetrexed
s pemetrexed alone [18], carboplatin plus gemcitabine
s gemcitabine alone [21,24], carboplatin plus paclitaxel
[
a
P
able 2
haracteristics of the 6 randomized trials included in the meta-analysis.
rial (reference) OS months Chemotherapy
regimen
Number of
patients
ukin et al. [18] 9.3
5.3
P:0.001
Carbo–Pem
VS Pem
103
102
orabito et al. [19] 5.9
3.0
P:0.039
Cis–Gem
VS Gem
28
28
osmidis et al. [24] 6.7
4.8
P:0.49
Carbo–Gem
VS Gem
43
47
eynolds et al. [21] 6.7
5.1
P:0.24
Carbo–Gem
VS Gem
85
85
ilenbaum et al. [22] 4.7
2.4
P:0.016
Carbo–Paclit
VS Paclit
49
50
e Chevalier et al. [23] 4.5
4.3
P: NA
Cis–Vino/Vind
VS Vino
75
46
S indicates overall survival; Carbo, Carboplatin; Cis, Cisplatin; Pem, Pemetrexed
-value; PS, Performance status; N/A, not available.ue; n., number of patients; N/A, not available.
e for each specific outcome.
s paclitaxel alone [22,25]; the other two trials compared
isplatin plus gemcitabine with gemcitabine alone [19] and
isplatin plus vinorelbine or vindesine with vinorelbine alone
23]. In nearly every trial characteristics were well balanced
etween two arms. In the trial by Le Chevalier et al. [23],
he two groups of patients receiving cisplatin (cisplatin plus
inorelbine and cisplatin plus vindesine) were considered
s a whole group, because the aim of this meta-analysis
s to explore the difference between platinum-based vs
on-platinum single agent chemotherapy. The extracted
ata, including number of patients, PS, age, histology,
tage, chemotherapy regimens, and outcomes, were reported
n Table 2. Data about ORR [18,19,21,22,24] and 1y-SR
18,21–24] were available from five studies. Finally, data
bout toxicity were available from 4 trials [18,19,21,24].
rimary and secondary endpoints were reported in Table 1.
Median age PS 2 (%) Squamous
histology (%)
Stage IV (%)
65
65
100 2.9
10.8
94.2
95.1
63
63
100 36
32
93
93
70.5
73
100 30
28
74
64
72.9
75
100 16.5
25.8
82
94
64
63
18 N/A 87
83
59
60
20 53
56
52
47
; G, gemcitabine; Pacl, paclitaxel; Vino, Vinorelbine; Vind, Vindesine; P,
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Citaon Arms Odds
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95% CI
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CPm vs Pm 2,71 1,06-6,93
Lil emb aum ,
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CPa vs Pa 2.91 0,94-9,03
Kos midis,    
JTO 2007
CG  vs G 3.64 0,69-19 ,15
Reynolds,
JCO 2009
CG vs G 3.71 1,29-10,65
Morabito,     
LC 201 3
CisG vs G 5.86 0,63-53 ,92
Random
combined
3.24 1,88-5,5 8
Heterogeneity Test
Cochran’s Q : 0.52             DF: 4             P-value: 0.97
F  single-
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ooled analysis showed a significant improvement in ORR
OR: 3.243; 95% CI: 1.883–5.583] and 1y-SR (OR: 1.743;
5% CI: 1.203–2.525) in favour of platinum-based doublet
hemotherapy. The pooled OR for ORR and 1y-SR was cal-
ulated using fixed-effect model, because of non-significant
eterogeneity between treatment effects (Q-test: P: 0.99 and
.76, respectively) (Figs. 2 and 3). In terms of toxicity, we
nalyzed only data on severe haematological toxicities, avail-
ble for five of six studies included. Pooled OR for grade 3–4
aematological toxicity rate showed a significant increase
n patients treated with platinum-based combination: grade
–4 anaemia (OR: 2.743; 95% CI: 1.359–5.536), grade 3–4
eutropenia (OR: 7.239; 95% CI: 3.725–14.073); grade 3–4
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J
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ig. 3. Comparison of the 1-year-survival rate between platinum-doublet arms and
nterval; C, Carboplatin; Cis, Cisplatin; Pm. Pemetrexed; Pa, Paclitaxel; G, Gemcita
he Oncologist; DF, degrees of freedom.agent arms of all included trials. 95% CI indicates 95% confidence interval;
, Journal of Clinical Oncology; LC, Lung Cancer; DF, degrees of freedom.
hrombocytopenia (OR: 12.881; 95% CI: 4.901–33.857)
Figs. 4–6). A summary of the Pooled Odds Ratios and 95%
I for each outcome examined is reported in Table 3.
.  Discussion
This meta-analysis included six randomized trials,
hich compared platinum-based doublets with single-agenthemotherapy in NSCLC patients and specific data for
S 2 patients. The results of these trials suggest that
latinum-based combination regimens are superior to single-
gent chemotherapy in the first-line treatment of this
itaon Arms Odds
Rao
95% CI
e Chevali er,
he O. 200 1
CisV vs V 0.95 0,34-2,67
os midis,    
TO 20 07
CG vs G 1,29 0,44-3,71
eyno lds ,  
CO 20 09
CG vs G 1,64 0,81-3,28
il emb aum ,
CO 20 05
CPa vs Pa 2,02 0,62-6,54
ukin,
JCO 20 13
CPm vs Pm 2,4 1,30-4,44
andom
ombined
1,74 1,20-2,5 2
Heterogeneity Test
Coch ran ’s Q : 2.75          DF:              P-value: 0.59
 single-agent arms of all included trials. 95% CI indicates 95% confidence
bine; V,Vinorelbine/Vindesine; JCO, Journal of Clinical Oncology; The O,
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Citaon Arms Odds
Rao
95% CI
Reynolds,
JCO 20 09
CG  vs G 2.12 0,76-5,84
Kos midis,    
JTO 20 07
CG vs G 2.98 0,36-24,5
Zukin,
JCO 20 13
CPm vs Pm 3,1 0,99-9,69
Morabito,     
LC 201 3
CisG vs G 25,5 0,44  -
1463,8
Random
combined
2,74 1,35-5,5 3
Heterogeneity Test
Coch ran ’s Q : 1.46           DF: 3             P-value: 0.69
Fig. 4. Comparison of the Grade 3–4 anemia rate between platinum-doublet arms an
interval; C, Carboplatin; Cis, Cisplatin; Pm. Pemetrexed; Pa, Paclitaxel; G, Gemci
of freedom.
Table 3
Summary of the pooled odds ratios and 95% CI for each outcome examined
in all included trials.
Outcomes Pooled odds ratios 95% CI
ORR 3.24 1.88–5.58
1-year-OS-rate 1.74 1.20–2.52
G3–4 Anemia 2.74 1.35–5.53
G3–4 Neutropenia 7.23 3.72–14.07
G3–4 Thrombocytopenia 12.88 4.9–33.85
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d-y-OS-R, 1-year survival rate; ORR, overall response rate; G3–4, grade
–4.
pecial population both in terms of ORR and 1y-SR,
espite an increase in severe haematological toxicities.
his literature-based meta-analysis confirms the results
chieved in the randomized trials devoted to PS 2 patients
18,19].
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ig. 5. Comparison of the Grade 3–4 neutropenia rate between platinum-doublet
onfidence interval; C, Carboplatin; Cis, Cisplatin; Pm. Pemetrexed; Pa, Paclitaxel; 
egrees of freedom.d single-agent arms of all included trials. 95% CI indicates 95% confidence
tabine; JCO, Journal of Clinical Oncology; LC, Lung Cancer; DF, degrees
However this meta-analysis has some weaknesses points.
ome included studies were specifically devoted to PS2
atients [18,19,21,24], 2 studies were not exclusively devoted
o this subset of patients [22,23]. The CALGB trial [22]
ompared carboplatin-paclitaxel with paclitaxel alone in 584
atients with advanced NSCLC. It showed a significant
mprovement in ORR and a trend toward improved survival
ithout statistical significance for combination arm in over-
ll population, while subgroup analysis of 105 patients with
S 2 (18%) showed not only a significant improvement of
RR (24% vs 10%), but as well of median OS (4.7 month
S 2.4 month) and 1y-SR (18% vs 10%; hazard ratio [HR]:
.6; P: 0.016), with nearly double survival benefit in favour
f platinum-based combination. Unfortunately the authors
id not report toxicities in the subgroup of PS2 patients.
o this is the only study included in our meta-analysis with
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issing haematological toxicity data. A French study [25]
f carboplatin-paclitaxel compared with weekly paclitaxel
lone was devoted to elderly patients with advanced NSCLC,
ut included 123 patients (27.3% of study population) with PS
. Anyway the extraction of specific outcome measurements
nd toxicity for PS2 patients is not possible and therefore we
ad to exclude this study.
Furthermore, most studies included in our meta-analysis
id not collect neither reported data on pre-existing patients’
omorbidities, while some of these collected them not uni-
ormly. This problem limited the chance of providing clear
onclusions about the PS 2 population. In general, the PS 2
epresents a heterogeneous and large group of patients, what
akes it necessary to better understand the role played by
ifferent factors (comorbidities, disease burden and tumour-
elated symptoms) in compromising PS to select a favourable
ubgroup of patients who could better tolerate platinum-
ased doublet chemotherapy. In fact it is conceivable that
latinum-based chemotherapy may lead to a clinical and sur-
ival benefit in patients whose poor PS is due to tumour
urden, whereas those who are relatively asymptomatic for
ancer, but are affected from symptomatic concomitant ill-
ess may not benefit from an aggressive treatment, which
ould worsen their clinical situation. In these patients a single-
gent treatment with a third-generation drug or BSC could
e considered as an alternative. Another point of discus-
ion regards the various treatment regimens in the included
tudies. In most studies included in our meta-analysis
18,21,22,24] patients received carboplatin-based regimen,
hile only in two [19,23] cisplatin-based chemotherapy was
dministered. It is well known that platinum-based regimens
epresent the standard treatment of advanced NSCLC patients
ithout activating EGFR or ALK mutations [6].
Several trials in the past compared regimens containing
isplatin vs carboplatin with conflicting results [26–33]. In
w
p
bl; G, Gemcitabine; JCO, Journal of Clinical Oncology; LC, Lung Cancer;
007, an individual patient data meta-analysis performed
y Ardizzoni et al. [34], including 9 of these trials and
omparing cisplatin VS carboplatin-based chemotherapy in
968 NSCLC patients, showed a significant improvement of
RR in favour of cisplatin arm (30% VS 24%; OR: 1.37,
 < 0.001), while no significant differences between two arms
ere observed in survival rate. A subgroup analysis showed a
ignificant increase of mortality rate in favour of carboplatin
rm in patients with non-squamous histology and in those
reated with a combination of carboplatin and a third genera-
ion drug (HR: 1.12, 95% CI: 1.01–1.23 and HR: 1.11, 95%
I: 1.01–1.21, respectively); severe thrombocytopenia was
lso more frequent with carboplatin regimen, while cisplatin
reatment was associated with more severe nausea, vomiting
nd nephrotoxicity. So the authors concluded that cisplatin-
ased third-generation regimens should remain the standard
eferences for the treatment of advanced NSCLC. However,
 similar more recent meta-analysis [35], including 10 trials
ith 3973 people, showed no difference between carboplatin-
ased and cisplatin-based chemotherapy in overall survival
HR: 1.00; 95% CI: 0.51–1.97) and 1y-SR (risk ratio: 0.98;
5% CI: 0.88 to 1.09), but confirmed higher RR in favour
f cisplatin arm (RR 0.88; 95% CI 0.79 to 0.99), and also a
ifferent toxicity profile between two drugs.
So, based on these conflicting and not conclusive results,
e may consider cisplatin and carboplatin as two equal
ffective options in the treatment of NSCLC population,
ut it is also clear from these analyses that cisplatin treat-
ent is associated with many serious side effects, including
ausea and vomiting, myelosuppression, neurotoxicity and
ephrotoxicity and often the need of hospitalization for pro-
onged hydration. Carbopatin on the other hand is associated
ith a lower incidence of non-haematological effects com-
ared to cisplatin and does not require prolonged hydration,
ut produces more profound myelosuppression (especially
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hrombocytopenia). Therefore we can conclude that it is eas-
er to administer carboplatin in every day practice The use
n combination with a third generation drug should be con-
idered as a favourable option in the treatment of special
opulation such as patients with a PS 2, who are historically
onsidered frail and at higher risk for severe toxicities. Indeed
aematological toxicity was more frequent and severe among
atients assigned to combination arm.
So, an interesting question in the modern clinical practice
or lung cancer management is how much intense should be
he treatment of PS 2 patients. Even if contradictory results
ere reported from prospective randomized trials compar-
ng platinum-based doublets vs single-agent chemotherapy
evoted to PS 2 patients, our meta-analysis supports the
vidence that platinum-based doublets are superior to single-
gent therapy in terms of ORR and survival rate, in spite of
n increase of severe haematological toxicities. Additionally,
espite the wide range of median OS differences, ranging
rom 0.2 to 4 months in all included studies, probably due
o the heterogeneity of both included patients and investi-
ated treatments, the pooled OR for 1y-SR indicates that
hose patients receiving platinum-based treatment have a 74%
igher probability of being alive after 1 year, with a significant
mpact for clinical practice.
Even if QoL may not be assessed in our meta-analysis
ecause of the lack of data in the included studies, data
vailable from two included trials that performed a formal
oL assessment [19,24] showed no statistically signifi-
ant differences between single-agent and platinum-based
ombination arms. Considering OS and QoL as the two
ost important endpoints for NSCLC first-line chemother-
py, we suggest that platinum-based combination may be
onsidered as a feasible treatment option in untreated PS
 patients with EGFR wild-type NSCLC. However this
onclusion should not be extended to overall PS 2 popu-
ation, due to the lack of comorbidity data in the included
tudies.
Further studies are needed about the comparison of differ-
nt carboplatin combinations, and also about the comparison
etween carboplatin- and cisplatin-based combinations, to
stablish the best treatment of NSCLC PS 2 patients. We
gree with the proposal by Zukin et al. about the introduction
f a formal comorbidity analysis as a stratification factor,
o better select subgroups of patients that may tolerate an
ggressive treatment [18].
.  Conclusion
In conclusion this meta-analysis suggests that platinum-
ased doublets are superior to single-agent therapy in the 1-st
ine treatment of PS2, NSCLC patients. In particular it sup-
orts the evidence that platinum-combination regimens are
uperior to single-agent both in terms of ORR and survival
ate in spite of an increase of severe haematological toxi-
ities. This information could change current treatment ofgy/Hematology 95 (2015) 306–317 313
hese patients, encouraging the use of platinum as front-line
herapy, but this conclusion could not be extended to over-
ll PS 2 population. We endorse here the stratification of PS2
atients according to the reason for their health status worsen-
ng (i.e. comorbidity or tumour-related symptoms). We argue
hat a selection of PS2 patients according with this classifi-
ation could help to identify those who could better tolerate
latinum-based doublets and achieve a greater efficacy from
his treatment.
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